Fusion Pharmaceuticals Inc. - FUSN STOCK NEWS

Fusion Pharmaceuticals (Nasdaq: FUSN) has received final court approval for its acquisition by a wholly-owned subsidiary of AstraZeneca. Under the deal, Fusion shareholders will receive $21.00 per share in cash upfront and an additional $3.00 per share contingent on a future regulatory milestone. The arrangement was approved by Fusion's shareholders on May 29, 2024, and is expected to close in Q2 2024, pending customary closing conditions. Post-completion, Fusion's shares will be delisted from NASDAQ.

Fusion Pharmaceuticals (Nasdaq: FUSN), a clinical-stage oncology company, announced that its shareholders approved the acquisition by AstraZeneca. The special meeting held on May 29, 2024, saw 80.83% of the 84,965,608 outstanding shares voting, with 99.92% in favor of the arrangement. The acquisition plan is subject to court approval and other customary conditions. If met, the transaction is expected to conclude in Q2 2024.

Fusion Pharmaceuticals Inc. announced the dosing of the first patient in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 in metastatic castration-resistant prostate cancer. The AlphaBreak trial is part of a registrational program for FPI-2265, a next-generation radioconjugate precision medicine for mCRPC patients. The trial aims to evaluate the safety and efficacy of FPI-2265 in patients previously treated with 177Lu-PSMA radiotherapy, with potential Phase 3 enrollment starting in 2025.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) reported financial results for the first quarter of 2024 and provided updates on clinical programs. The company presented positive interim data from the TATCIST trial of FPI-2265 in mCRPC at the AACR Annual Meeting. Fusion also announced an acquisition by AstraZeneca for up to $2.4 billion, with the transaction expected to close in Q2 2024. Additionally, Fusion is progressing various clinical-stage programs, including FPI-1434 and FPI-2059, showcasing promising results and future development plans.

Fusion Pharmaceuticals Inc. announces a special meeting of shareholders to approve an arrangement with AstraZeneca plc, where AstraZeneca will acquire all outstanding shares for US$21.00 per share in cash plus a contingent value right of US$3.00 per share. The meeting is set for May 29, 2024, with a record date of April 16, 2024, and will be held virtually. The board of directors unanimously recommends shareholders vote FOR the arrangement.

Fusion Pharmaceuticals Inc. presents promising interim data on FPI-2265 for metastatic castration-resistant prostate cancer at AACR 2024. Results show efficacy in heavily pretreated patients, with a PSA50 response rate of 50%. The drug demonstrates improvement in secondary endpoints and is generally well-tolerated. Fusion plans to initiate Phase 2/3 trials in 2024 for further development.

Fusion Pharmaceuticals Inc. announced a definitive agreement to be acquired by AstraZeneca, with a focus on their FPI-2265 Phase 2/3 program for metastatic castration-resistant prostate cancer. The company reported financial results, including a $2 billion transaction value, and provided updates on clinical programs and corporate developments.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) to be acquired by AstraZeneca in a $2.4 billion transaction. Fusion's radioconjugate targeting PSMA for prostate cancer and R&D capabilities key in the acquisition.

Fusion Pharmaceuticals Inc. announced the grant of stock option awards to four employees outside the 2020 Stock Option and Incentive Plan. The options allow the purchase of 245,300 shares at an exercise price of $10.79 per share, with a ten-year term and vesting over four years. This move aims to incentivize employee retention and align interests with shareholders.